Under the licensing agreement between Depomed and Mallinckrodt, a subsidiary of Covidien, Depomed will receive a one-time upfront payment of $4 million, and could receive up to $64 million in additional development milestone payments over the next several years.
In addition, Covidien will pay Depomed a royalty on sales of products developed under this license agreement. Covidien will be responsible for all development other than certain initial formulation work. Covidien will pre-pay Depomed for the initial formulation work performed by Depomed under the collaboration.
Depomed will retain the exclusive option to promote the products developed under this license agreement within the obstetrics/gynecology specialty field. Once Depomed begins to promote these products, Covidien will pay Depomed a significantly higher royalty on the resulting net sales in this specialty.
Carl Pelzel, president and CEO of Depomed, said: “We feel this transaction reflects the value of our technology and its ability to engender compounds with new, meaningful product differentiation. In addition, this agreement provides Depomed with another attractive option for co-promotion in the obstetrics/gynecology specialty.”